| Name | Title | Contact Details |
|---|---|---|
Martina KOVAC |
VP, Global Product Development-Vaccines | Clinical Research at PPD, part of Thermo Fisher Scientific | Profile |
Jai Balkissoon |
Vice President, Immuno-Oncology,Global Product Development | Profile |
Sudhakar Sridharan |
Executive Medical Director, Global Product Development, Rheumatology & Immunology | Profile |
Louis Griffel |
Executive Medical Director - Global Product Development | Profile |
Binh Nguyen |
VP Global Product Development | Profile |
Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company`s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase-naïve and pre-treated patients, and is expected to enter a registrational study in the second half of 2019. Turning Point`s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to overcome treatment resistance common in other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.
ViroPharma Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.
Entrada Therapeutics is a biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines, Endosomal Escape Vehicles (EEV™), to engage intracellular targets that have long been considered inaccessible and undruggable. The Company`s EEV therapeutics are designed to enable the efficient intracellular delivery of a wide range of therapeutics into a variety of organs and tissues with an improved therapeutic index. Through its proprietary, highly versatile and modular EEV Platform, Entrada is building a robust development portfolio of oligonucleotide-, antibody- and enzyme-based programs for the potential treatment of neuromuscular disease, immunology, oncology and diseases of the central nervous system.
Akero Therapeutics is developing best-in-class medicines that restore metabolic balance to treat non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.